The influential event is organised alongside the largest gathering of healthcare financiers and executives and will feature a host of emerging life science companies presenting new developments to investors at San Francisco Marriot Marquis from January 12 to 13.
Dr Eric Mayes, CEO at Endomag (pictured), will present at 11.45am PST on January 12. He will talk about the impact of receiving Investigational Device Exemption (IDE) approval from the United States Food and Drug Administration (FDA) and the business’ expansion into new markets.
Dr Mayes said: “We’re committed to solving challenges in cancer care, and bringing access to it for all. So far our success has been in diagnostics, but the use of magnetics as a minimally invasive treatment also has huge potential in therapeutics.
“As a result of our acquisition of the ACT portfolio earlier this year, we are now developing our magnetics portfolio to cover both diagnostic and therapeutic applications for cancer care. We have some very exciting plans for 2015 and beyond, and look forward to highlighting our activity at OneMedForum.”
Endomagnetics is dedicated to improving the global standard cancer care for everyone, everywhere, by developing a new, effective clinical platform that uses safe magnetic fields to power diagnostic and therapeutic devices.
Endomagnetics’ first approved products are the Sentimag® and Sienna+®. Sienna+® is a CE marked magnetic tracer approved across the European Union and Australia for use with the Sentimag® detection system. Sienna+® is injected into the body and the Sentimag® is used to track its presence, locating lymph nodes as part of a sentinel lymph node biopsy (SLNB) procedure.
By avoiding the need for traditional radioactive isotopes in sentinel lymph node biopsy, Sentimag® and Sienna+® improve workflow and lower costs, enhance patient comfort and quality of life, and provide a better standard of care available to everyone, everywhere.
Visit www.endomag.com
________________________________________________